Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2018
Terms & Conditions


Featured Events

CAR-T clinical trials have demonstrated unparalleled success achieving remission rates of up to 94% in multiple hematologic malignancies…is CAR-T therapy what we’ve been waiting for? Join 18+ thoug...

The approval of Besponsa and re-approval of Mylotarg has injected huge excitement into the ADC field. Now with 4 approved drugs, over 65 candidates in clinical development and many more in preclinic...



Skip to toolbar